🇺🇸 FDA
Patent

US 11219604

Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

granted A61KA61K31/56A61K31/58

Quick answer

US patent 11219604 (Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith) held by Eupraxia Pharmaceuticals USA LLC expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Eupraxia Pharmaceuticals USA LLC
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/56, A61K31/58, A61K9/0024, A61K9/5026